Veterinary Reference Laboratory Market Worth $5.13 Billion By 2025

The global veterinary reference laboratories (VRL) market is expected to reach USD 5.13 billion by 2025, according to a new report by Grand View Research, Inc. Increase in incidence of zoonotic diseases is a key driving factor for market growth. Increase in adoption of integrated diagnostic systems coupled with information ecosystems for veterinary diagnostics is anticipated to fuel development.

Rise in demand for advanced diagnostic tests and growing awareness amongst consumers are some of the factors expected to boost demand over the coming years. Moreover, companies are investing in R&D for the advancement of test kits for cost-effective diagnosis & monitoring of animal health, which is expected to boost growth. Some of the advancements in this market include efficient information management systems used in animal diagnostic applications, vaccine banks, and mobile apps for continuous monitoring. High focus toward innovation in veterinary health is anticipated to fuel the demand for reference labs. For instance, Innovative Medicines Initiative (IMI) is a public-private partnership that supports pharmaceutical innovations in Europe.

In addition, MediLab Secure, a laboratory network project was established, which aims to identify emerging viruses& pathogens in 19 countries in the Mediterranean regions and 57 labs were involved. Furthermore, increase in the number of government initiatives to promote veterinary diagnostics products is presumed to drive the overall growth.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/veterinary-reference-laboratory-vrl-market

Further Key Findings From the Study Suggest:

The clinical chemistry analyzers segment held the dominant share of the market as of 2016 owing to growing demand for veterinary diagnostics products
Increase in instances of contamination in pet foods that cause severe illnesses and deaths amongst animals is expected to boost the demand for toxicology testing services
Production animals accounted for largest revenue share in 2016 owing to their highest consumption rate
The market was dominated by North America and is expected to retain its position throughout the forecast period
Presence of prominent industry players, advanced healthcare infrastructure, and high healthcare expenditure are some of the factors responsible for growth
Companies offering reference laboratories are focusing on the development of cost-effective diagnostic solutions for animal health
IDEXX Laboratories, Inc. held a dominant share owing to its presence across the globe and a wide product portfolio of advanced diagnostic tests
Strategies such as regional expansion, new product developments, merger & acquisitions, and research collaborations are anticipated to propel growth
For instance, in January 2017, Mars, Inc. announced the agreement for acquiring VCA Inc. in a probe to capture higher share

In Vitro Diagnostics Market Size Worth $85.8 Billion By 2027

The global in vitro diagnostics (IVD) market is expected to reach USD 85.8 billion by 2027, according to a new report by Grand View Research, Inc. It is projected to exhibit a 4.4% CAGR over the forecast period. The development of simplified diagnostic tests is expected to drive growth. For instance, Cepheid’s Xpert HCV VL Fingerstick received CE-IVD clearance in September 2018. This test identifies and measures HCV RNA levels from a fingerstick blood sample.

Key players are developing new products and undertaking strategic initiatives, such as collaborations, mergers and acquisitions to gain greater market share and to expand their product portfolio. For instance, in February 2018, a product named PAXgene Blood ccfDNA tube was made available by BD for non-invasive prenatal testing and cancer diagnosis and application in the European Economic Area (EEA) and Switzerland. PAXgene Blood ccfDNA tube was developed by Qiagen-PreAnalytiX GmbH and BD in a joint venture.

The rising geriatric population and favorable government regulations to spur the approval process of medical devices are the factors expected to drive the market over the forecast period. For instance, in August 2018, the approval process for IVD was eased in an amended provision in the Fourth Schedule of Medical Devices Rule by the central government of India.

Furthermore, increasing demand for early diagnosis to strategize complete treatment plans for patients by the physicians is projected to fuel the demand for user-friendly in vitro diagnostic products. For instance, in July 2017, bioMerieux for VITEK MS received the U.S. Food and Drug Administration (FDA) approval. It is a mass spectrometry system that rapidly identifies pathogens, such as Nocardia mycobacteria, and molds.

Reagents held the largest market share in 2019, owing to the development of analytical laboratory automation coupled with a high usage rate of reagents. For instance, in July 2018, Surmodics, Inc. launched MatrixGuard Diluent that blocks matrix or assay signal and maintains intended signals.

The increasing prevalence of cancer, cardiovascular disorders, diabetes, and other diseases is expected to accelerate the demand for in vitro diagnostics in the forthcoming years. According to Cancer Research UK, in 2018, about 17 million new cancer cases were reported across the world. It has estimated that the incidence rate of the disease will witness a 62% rise from 2018 to 2040. The liver, stomach, breast, lung, and colorectal are the most common types of cancer.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-ivd-market

Further key findings from the report suggest:

The molecular diagnostics segment is expected to witness the fastest growth over the forecast period, owing to the high usage of the technology for disease diagnosis
The infectious disease application segment dominated the market in 2019 due to the rising prevalence of tuberculosis, hepatitis, and other infectious diseases
North America dominated the in vitro diagnostics market in 2019, owing to the presence of key players and a rise in the launch of new products in major countries like the U.S. and Canada
Asia Pacific is expected to exhibit the fastest CAGR over the forecast period owing to the number of products that are being launched in hospitals to provide an accurate diagnosis
Major IVD market players are Qiagen; Danaher; Becton, Dickinson and Company; Siemens Healthineers; F. Hoffmann-La Roche Ltd.; Hologic, Inc. (Gen-Probe); bioMerieux SA; Abbott Laboratories; Cepheid; and Sysmex Corporation

Companion Animal Diagnostics Market Size Worth $4.1 Billion By 2026

The global companion animal diagnostics market size is expected to reach USD 4.1 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.4% during the forecast period. The anticipated rise in companion animal population would increase the demand for veterinary healthcare facilities. According to a 2018 report by the American Pet Products Association (APPA), the overall spending in the U.S. pet industry has increased by 4.1% from 2016 to 2017. Moreover, veterinary care spending has increased by 7% from USD 15.95 billion in 2016 to USD 17.07 billion in 2017.

The demand for advanced diagnostic facilities for rapid and accurate testing of sample is propelling the growth of companion animal diagnostics over the forecasted period. The approvals and the new product launches by the key industry players to deal with the rising demand are driving the market. The companies are constantly trying to develop innovative devices to tap the enormous growth potential of the market. For instance, Idexx Laboratories gained a significant presence in the market by launching the new chemistry analyzer. Zoetis increased their penetration by acquiring one of the top veterinary diagnostics company Abaxis in July 2018.

Moreover, the rising concern of people for their pets leads to an increase in insurance claims. Most of the pet insurance covers major chronic conditions except any pre-existing one. The millennials are considered an attractive target population for the companies playing in this space. Millennials around the world consider pets and presence of animals good for their emotional and physical health. The demand for easy to administer and rapid diagnosis is anticipated to further boost the revenue.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/companion-animal-diagnostics-market

Further key findings from the report suggest:

In 2018, clinical pathology held the largest revenue share of the companion animal diagnostics market in terms of application owing to its wide usage for multiple disease diagnosis
Clinical biochemistry acquired major market share in 2018 within the technology segment and is expected to expand at the fastest CAGR by 2026. The growth can be attributed to the increased use of clinical chemistry analyzers and glucose monitors for rapid diagnosis of some chronic diseases in pets
On the basis of animal type, cats was the fastest growing segment in 2018 and is expected to register a CAGR of over 8.00% by 2026, majorly owing to increasing prevalence of chronic diseases such as arthritis and diabetes among others
The point of care/in house testing segment is expected to showcase lucrative growth over the forecast period, attributed to the rapidity, efficiency, and convenience of these tests
Asia Pacific is expected to emerge as the fastest growing region over the forecast period. North America held the largest revenue share in 2018 due to the presence of major industry players in the region
Some of the major market players include Zoetis Inc.; Idexx Laboratories Inc.; Heska Corporation; Thermo fisher Scientific; and Neogen

Respiratory Syncytial Virus Diagnostics Market To Reach $1.2 Billion By 2022

Global Respiratory Syncytial Virus (RSV) diagnostics market is expected to reach USD 1.2 billion by 2022, according to a new study by Grand View Research Inc. Increasing neonatal population suffering from respiratory conditions including RSV infections and supportive initiatives for diagnosis of newborns by the healthcare providers are expected to be vital impact rendering drivers for RSV diagnostics market.

According to the statistics provided by the WHO, hospitalization of over 150,000 children (below the age of five) and about 14,000 deaths in geriatric patients occurred in the U.S. in 2014 due to RSV infections. This is anticipated to trigger demand for testing of these conditions over the forecast period.

Furthermore, the global birth rate as of 2014 is 18.7 births per 1,000 individuals, which is predicted to increase the infant population substantially over the next seven years. According to the statistics, it is estimated that about 134.2 million births took place in 2014, which are prone to RSV infections and require diagnosis, thus forming a large market base.

In 2010, Save Babies Through Screening Foundation (SBTS) entered in a partnership with World Solutions Against Infectious Disease (WSAID) as an attempt to promote higher screening of newborns for infectious diseases, metabolic disorders, and hearing disabilities.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/respiratory-syncytial-virus-diagnostics-market

Further key findings from the study suggest:

Chromatographic immunoassay technology based products are expected to witness the fastest growth at a CAGR above 10.0% over the next seven years owing to their higher specificity than molecular diagnostic products. The commercially available test kits include Binax Now RSV, QuickLab RSV Test, Remel Xpect, and RSV Respi-Strip.
Hospitals are predicted to dominate the RSV diagnostics market followed by home care. Together, they are expected to contribute over 50.0% of the market share in 2022. Increasing demand for home care diagnostic devices by patients is anticipated to drive growth of the segment over the next seven years.
North America is anticipated to dominate the market and contribute a revenue share of over 40.0% by 2022. Rising awareness among the population base and favorable initiatives by the government agencies such as the WHO, PAHO, and WSAID to initiate and implement newborn screening are expected to drive growth.
Key players of the market include Alere Inc., EMD Millipore, BD and Company, Ortho Clinical Diagnostics, Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific Inc. CLIA waiver and launch of RSV assays by companies like Roche Diagnostics, Becton Dickinson and Company, and Alere Inc. are expected to boost market growth over the forecast period.

In Vitro Diagnostics Market Size Worth $100.8 Billion By 2026

The global in vitro diagnostics market size is expected to reach USD 100.8 billion by 2026 registering a CAGR of 4.75%, according to a new report by Grand View Research, Inc. Favorable government regulations supporting approval process of medical devices and rising geriatric population are among the key factors driving the market. For instance, in August 2018, the central government of India amended provisions in the Fourth Schedule of Medical Devices Rule to ease the approval process for IVD devices. In July 2017, bioMerieux received an FDA approval for VITEK MS, its mass spectrometry system for rapid identification of pathogens, such as mycobacteria, molds, and Nocardia species.

In addition, various initiatives by private and public organizations are projected to fuel market growth. For instance, In July 2018, NAMSA-a Medical Research Organization-launched its “Uniquely IVD” development services to expedite the commercialization of IVD devices for global manufacturers. NAMSA is collaborating with global regulatory bodies to investigate the international regulatory framework and delivers highly reliable IVD development outputs related to clinical research initiatives, quality, and regulatory systems.

Furthermore, rising need for onsite and early diagnosis and treatment plans is anticipated to accelerate the demand for highly accessible IVD products. Rising prevalence of diseases, such as Cardiovascular Disorders (CVDs), cancer, and diabetes, are also expected to increase the demand for IVD. According to Cancer Research U.K., in 2018, about 17 million cancer cases were reported. Key companies, such as Becton, Dickinson and Company; Hologic, Inc. (Gen-Probe); bioMerieux SA; and F. Hoffmann-La Roche Ltd.; are focusing on product development, collaborations, and M&A to increase their market share and product portfolio.

For instance, in February 2018, BD announced the availability of PAXgene Blood ccfDNA tube (CE-IVD marked) used for cancer and non-invasive prenatal testing application in Switzerland and the European Economic Area. This product was developed by a joint venture of BD and Qiagen-PreAnalytiX GmbH. In addition, in September 2018, Cepheid received CE-IVD clearance for Xpert HCV VL Fingerstick used to detect and quantify HCV RNA levels from fingerstick blood sample.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/in-vitro-diagnostics-ivd-market

Further key findings from the study suggest:

Reagent product segment held the largest market share of 64.9% in 2018 owing to the high usage of reagents in IVD testing
Molecular diagnostics is expected to witness the fastest growth over the forecast period owing to its high usage in detecting various diseases
Infectious disease application segment led the global IVD market in 2018 and is projected to maintain the dominance during the forecast period
Asia Pacific region is expected to exhibit the fastest growth from 2019 to 2026 on account of rapidly improving healthcare infrastructure and presence of large target population base